VANCOUVER, Nov. 21 /CNW/ - Data supporting Protox Therapeutics Inc.'s (TSX-V: PRX) PORxin technology and its lead compound, PRX302, were presented at the 18th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics” held in Prague, Czech Republic, November 9th & 10th.
